DARA BioSciences, Inc. (DARA) announced today that company entered into an exclusive agreement with The Helsinn Group of Switzerland for U.S. commercial rights to Gelclair®. DARA plans to launch Gelclair, FDA-cleared product indicated for the treatment of oral mucositis, in the first quarter of 2013. Oral mucositis market is approximately 400,000 patients annually according to […]